The stock was not able to be pushed down at the end of the day by shorts at yesterdays close and looks to open strong today at $2.11
GeoVax Announces Peer-Reviewed Publication in NPJ Vaccines of Preclinical Data for Vaccine Candidate Against Sudan Ebolavirus Showing 100% Protection With a Single Immunization
ATLANTA, GA, July 28, 2022 (GLOBE NEWSWIRE) — via NewMediaWire – GeoVax Labs, Inc. (Nasdaq: GOVX), a biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, announced today the publication of a peer-reviewed animal efficacy study of its modified vaccine Ankara (MVA) vectored vaccine against Sudan ebolavirus (SUDV). The study was published in Nature Partner Journals (NPJ) Vaccines.
*editors will be trading in the stock throughout the day as opportunities to buy and sell present themselves